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Transforming growth factor-1 antisense
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Background: The main cause of occlusion and vein graft failure after peripheral and coronary arterial reconstruction is
intimal hyperplasia. Transforming growth factor -1 (TGF-1) is a pleiotropic cytokine known to have powerful effects
on cell growth, apoptosis, cell differentiation, and extracellular matrix synthesis.
Methods: To investigate the role of TGF-1 in intimal hyperplasia, we used adenovirus to deliver to superficial epigastric
vein messenger RNA (mRNA) antisense to TGF-1 (Ad-AST) or the sequence encoding the bioactive form of TGF-1
(Ad-BAT). Infection with “empty” virus was used as a control (Ad-CMVpLpA). The treated vein was then used for an
interposition graft into rat femoral artery. Grafts were harvested at 1, 2, 4, and 12 weeks and formalin-fixed for histologic
studies or placed in liquid nitrogen for mRNA studies.
Results: Ad-AST treatment resulted in an overall reduction of TGF-1 expression (P  .001), and Ad-BAT treatment
resulted in an overall increase in TGF-1 expression (P  .007). Histologic analysis showed Ad-AST caused reduced
collagen build up in the neointima at 12 weeks (P .0001). Immunohistochemical staining for h-caldesmon at 12 weeks
indicated Ad-AST increased smooth muscle cells throughout the vessel wall compared with Ad-CMVpLpA (P  .0024)
or Ad-BAT (P  .04). Ad-AST also resulted in reduced CD68-positive cells in the media/adventitia (P  .005 vs
Ad-CMVpLpA, P  .01 vs Ad-BAT). To further understand how Ad-AST was influencing the build up of collagen, we
performed quantitative polymerase chain reaction on complimentary DNA (cDNA) from homogenates of the vein grafts.
Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) was increased at 1 week by Ad-BAT (P  .048 vs Ad-
CMVpLpA) and decreased by Ad-AST at all time points (P < .038). The mRNA for collagen-1 -1 was decreased by
Ad-AST at 2, 4, and 12 weeks (P < .05) and increased by Ad-BAT at 1 week (P  .01).
Conclusions: TGF-1 antisense treatment of vein grafts prevents the accumulation of collagen in the neointima in part by
(1) changing the proportions of the cell types populating the vein graft wall, (2) reducing the mRNA for TIMPs, and (3)
reducing the amount of collagen mRNA. With the Ad-AST and Ad-BAT treatments, we have been able to tip the
maturation of the vein graft toward positive remodeling (artery-like phenotype) or toward negative remodeling
(fibroproliferation and stenosis), respectively. ( J Vasc Surg 2006;43:1028-36.)
Clinical Relevance: The main cause of occlusion and graft failure after peripheral and cardiac arterial reconstruction is
intimal hyperplasia. The study of the mechanisms and mediators of intimal hyperplasia, including TGF-1, should lead
to future gene therapies to prevent or limit intimal hyperplasia. Ultimately, the goal of this research is to provide the
clinician with a safe and reliable method of preconditioning vein to make it a more reliable conduit for arterial repair.Choices are limited for peripheral vein grafts. Autoge-
nous saphenous vein has been found to be superior to
polytetrafluoroethylene, Dacron, and human umbilical
vein. However, even autogenous saphenous vein grafts
have high 5-year failure rates of 26% for above-knee femo-
ropopliteal bypass,1 25% for coronary bypass,2 and 38% for
infrainguinal bypass.3
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1028Intimal hyperplasia is often the cause of vein graft
failure and is characterized by cellular proliferation and
extracellular matrix deposition in the innermost layer of the
vessel wall. This process results in progressive luminal nar-
rowing. Although understanding of intimal hyperplasia
development is limited, one theory suggests that it begins
as a healing and vessel-remodeling response to surgical
manipulation and arterial pressure that evolves into a
chronic condition of unchecked cellular proliferation and
extracellular matrix production.
Vein tissue explanted from the patient provides a
unique opportunity for gene therapy of the target vessel
with minimal systemic exposure of the patient to the treat-
ment.4,5 Cytokines, regulatory proteins that act as intercel-
lular mediators, are responsible for the development of
intimal hyperplasia can be targeted by gene therapy during
the operation in an attempt to modify the response of the
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eventual failure of the vein graft.
Transforming growth factor-1 (TGF-1) is a ubiqui-
tous pleiotropic cytokine that is important in inflammation
and wound healing as well as in normal growth and devel-
opment. This growth factor is known to have powerful effects
on cell growth, apoptosis, cell differentiation, and extracellular
matrix synthesis. Increased expression of TGF-1 has been
demonstrated in human atherosclerotic plaque,6 restenotic
arteries,7 and vein grafts.8 Upregulation of TGF-1 is also
associated with other fibrotic diseases such as systemic
sclerosis and liver cirrhosis. Transfection of an expression
vector encoding TGF-1 into porcine arteries resulted in
increased intimal hyperplasia and procollagen production.9
Matrix metalloproteinases (MMPs) are responsible for
extracellular matrix degradation. The tissue inhibitors of
matrix metalloproteinases (TIMPs) block the action of the
MMPs.10 Usually, a decrease in MMPs (or an increase in
TIMPs) is expected to be associated with fibrotic disease.
Specific MMPs have additional roles in the progression of
fibrotic disease. Some MMPs are essential to cell migration, 11
and other MMPs can activate latent TGF-1.12
In our previous work, we showed that the Ad-AST
(TGF-1 antisense treatment) adenovirus construct was
able to knock-down TGF-1 messenger (mRNA) and pro-
tein expression in a rat femoral artery vein graft model and
mitigate intimal hyperplasia.13 In these studies, we investi-
gated the effect of Ad-AST on some of the factors associ-
ated with intimal hyperplasia. We hypothesized that Ad-
AST treatment of the vein grafts would result in reduced
collagen mRNA, reduced TIMPs mRNA, and less collagen
accumulation; whereas, Ad-BAT treatment of the vein
grafts (adenovirus expressing the mRNA for the bioactive
form of TGF-1) would result in increased collagen mRNA,
increased TIMPs mRNA, and more collagen accumulation.
We also investigated the effect of these treatments on smooth
muscle actin-positive cells (smoothmuscle cells andmyofibro-
blasts), CD68-positive cells (monocytes and macrophages),
and h-caldesmon–positive cells (smooth muscle cells).14-16
METHODS
Adenoviral transduction, microsurgery, and harvest.
Rat epigastric vein-to-femoral artery interposition grafts
were placed and harvested as previously described.13
Grafts were harvested at 1 week, 2 weeks, 4 weeks, and 12
weeks after grafting. The patency rate of harvested grafts
was 95%, with nonpatent grafts associated with technical
errors. Occluded grafts were not used in the analysis, and
another graft was implanted to take its place. Animal care
complied with the Principles of Laboratory Animals (for-
mulated by the National Society for Medical Research)
and the Guide for the Care and Use of Laboratory Animals
(National Academy Press). Procedures were approved by
the Research Animal Resources Center at the University of
Wisconsin-Madison.
For adenoviral transduction, 8 mm of freshly harvested,
cannulated, and irrigated epigastric vein was allowed to
passively dwell for 20 minutes ex vivo in an adenoviral solu-tion (107 plaque-forming units/mL). The three treatments
were (1) infection with adenovirus expressing mRNA anti-
sense to TGF-117 (Ad-AST), (2) infection with adenovirus
without any expressing gene (Ad-CMVpLpA), and (3) ade-
novirus expressing TGF-1 mRNA in the sense orientation
(Ad-BAT). The Ad-AST construct expresses the antisense
mRNA to the full-length TGF-1 protein (coding region
plus 130 bp of 5= untranslated region, 1303 bp), which
includes the latency-associated protein (pro region). The
sequence in the Ad-BAT construct has been manipulated
so that the protein produced is expressed in a bioactive
form and does not require activation.18 Each construct uses
the cytomegalovirus (CMV) promoter.
RNA extraction, reverse transcription, and quanti-
tative polymerase chain reaction. After the graft was
homogenized for approximately 15 seconds in 0.2 mL of
ice-cold buffer containing protease and ribonuclease inhib-
itors, a 0.05 mL aliquot of the homogenate was immedi-
ately transferred to 0.8 mL Trizol (Invitrogen, Carlsbad,
Calif) and vortexed to denature any ribonucleases. Glyco-
gen was used as a carrier to increase the yield of mRNA.
Chloroform extractions, washes, and precipitations were
performed. Purity and yields were determined by spectro-
photometry. Northern analysis has shown this method to
yield high quality RNA. The remaining 0.15mL of homog-
enate was used in an enzyme-linked immunoabsorbent
assay (ELISA) (see below).
Dnase-treated RNA (DNA Free, Ambion, Austin,
Texas) (1 to 5g) was reverse transcribed using Superscript
II (Invitrogen) according to the manufacturer’s instruc-
tions. The resulting cDNA was ribonuclease-treated
(RNase H, Invitrogen) and stored at –20°C until use.
Yields of cDNA were quantified by fluorescence spectrom-
etry and samples were diluted to 20 ng/L.
For each quantitative polymerase chain reaction (qPCR)
run on the Rotor-Gene 2000 (Corbett Research, Sydney,
Australia), we pipetted four standard curves for each of the
genes of interest and a standard curve for the housekeeping
gene hypoxanthine phosphoribosyltransferase, hprt.19 The
hprt gene has been validated as a reference gene by com-
paring it with three other housekeeping genes across our
treatments and time points and finding it to be the most
stably expressed of the four genes. Four reactions of each
sample (using 2, 1, 0.5, and 0.25 ul of sample) were run for
each gene. Cycle threshold vs  appropriate standard curve
was used to determine copies of col1a1, mmp-2, mmp-9,
and timp-1 per copy of hprt. Comparing the results from
reactions using different amounts of sample confirmed that
the reaction efficiencies were consistent and the measure-
ments were quantitative. The four estimates of the gene of
interest normalized to copies of hprt were then averaged to
give the result for each sample.
ELISA. To each 0.15 mL of homogenate, 1.5 L of
Triton X-100 (Sigma, St Louis, Mo) was added. After
mixing, the solution was incubated on ice for 30 minutes
with vortexing every 10 minutes. Particulates were pelleted
by centrifugation (15,000g for 15 minutes) at 4°C. ELISA
experiments for bioactive TGF-1 were performed on su-
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Madison, Wis) instructions using 96-well half-area plates.
Histochemistry. Through the use of the Gomori tri-
ple stain, different regions of the graft were stained accord-
ing to their composition. After heat-treating the tissue in
Bouin’s solution (Fisher, Fairlawn, NJ), three different
stains were used in succession to stain the different types of
tissue. Weigert’s iron hematoxylin (equal parts of alcoholic
hematoxylin and iron chloride) was used to stain all elastin
tissue and all chromatin black. Aldehyde fuscin was then used
to stain muscle cells and myofibroblasts red. Trichrome
light green stain (Fisher) was used to stain collagen green.
After staining was completed, the section was dehydrated
and then mounted using Permount (Fisher).
For staining specific to cell type, monoclonal primary
antibodies diluted in phosphate-buffered saline (PBS) con-
taining 0.2% bovine serum albumin (BSA) were used:
smooth muscle actin (clone 1A4 FITC conjugate at 1.75
g/mL, Sigma), CD68 (clone ED1 at 5 g/mL Serotec,
Raleigh, NC), and h-caldesmon14-16 (clone HHCD at 15
g/mL, Sigma). Secondary antibody for the unconjugated
primary antibodies was goat antimouse immunoglobulin
G1 Alexa Fluor 568 at 5 g/mL (Molecular Probes, In-
vitrogen).
Antigen retrieval (1 hour at 95°C in 1x 10 mM Tris-
HCl, pH 7.6, 1mM EDTA) (TE) was performed before
blocking nonspecific binding with 2% BSA in PBS. Sudan
Black, 0.3% in 70% ethyl alcohol (Sigma), acted as a general
Fig 1. Ad-AST and Ad-BAT are effective at changing the expres-
sion of bioactive transforming growth factor 1 (TGF-1) protein
in rat vein grafts. Ad-AST decreased TGF-1 expression vs Ad-
CMVpLpA (‘P  .001); Ad-BAT increased TGF-1 expression
vs Ad-CMVpLpA (P  .007). The difference between Ad-AST
and Ad-BAT was also significant (#P  .001). These P values
represent differences between treatment groups across all time
points (there was not a significant time by treatment effect). The
grafts were harvested at the indicated time points, rinsed with
phosphate-buffered saline, and homogenized. The supernatants
analyzed by enzyme-linked immunoabsorbent essay, which was
specific for bioactive TGF-1. For each treatment/time point, n
5 vein grafts. Error bars represent means  SEM.stain and blocked background fluorescence.Videomorphometry. Images of vein graft cross sec-
tions were captured by using a Nikon (Tokyo, Japan)
microscope and Olympus (Melville, NY) DP70 color cam-
era. Areas of red or green staining were measured using
MetaMorph imagine analysis software Universal Imaging,
Downingtown, Penn).20 For each red or green stain, a
range of red, green, and blue pixel intensities were defined to
identify stained cells but exclude unstained cells. Once this
range was determined, it was saved and used by the Meta-
Morph software to identify stained cells on all the sections
with no further operator input. The internal elastic lamina
was used to define the boundary between the neointima
and the media.
Statistical methods. To eliminate sampling bias due
to intimal hyperplasia eccentricity, starting 3 mm from the
anastomosis, four 5-m sections 800 m apart were aver-
aged. For each time point, a mean of all grafts (n 5) were
derived. Rat assignments to groups were randomized to
both treatment and time point, and this randomized design
was carried over into the immunohistochemical analysis so
that if there were day-to-day or slide-to-slide variations in
staining, the biases would average out to be zero. This
ensured that biases between experimental groups were, on
average, zero. Because of this, we can be confident that any
statistically significant differences we detected between
treatment groups or over time within a group were caused
by the experimental treatments.
All analyses were performed using SAS statistical soft-
Fig 2. Changes in vein graft morphometry at 12 weeks with
Ad-AST and Ad-BAT treatments. Grafts were transfected before
implantation with adenovirus that expressed either antisense to
TGF-1 (top left) or mRNA for bioactive TGF-1 (bottom left). A
graft transfected with adenovirus not expressing a gene (control,
top right) and ungrafted epigastric vein (bottom right) are also
shown. In contrast to Ad-CMVpLpA and Ad-BAT, Ad-AST shows
very little collagen (green) in the neointima (N). The Ad-AST was
also the only group that contained areas of red staining resembling
that seen in the medial layer of arteries. Nuclei and elastin stained
purple. Arrows indicate the internal elastic laminas. L, Lumen; A,
adventitia/media. Each photomicrograph was taken at original
magnification 100; insets are at 400.ware (SAS Institute, Inc, Cary, NC). P  .05 was consid-
02 vs A
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and four time points were made by using an analysis of
variance (ANOVA) model. After log-transforming the val-
ues (this produces fewer extreme values and more equiva-
lent group variances) to better meet the assumptions of the
ANOVA, SAS PROC GLM was used to test the main
effects (time and treatment) and possible interactions (time
by treatment). If there was a significant interaction effect, as
noted in the text, treatments were compared at each indi-
vidual time point. If there was not a significant interaction
effect, any time effect was accounted for in the comparison of
themain treatment effect. Values are expressed asmean the
standard error of the mean (SEM).
RESULTS
Effectiveness of the Ad-AST and Ad-BAT treat-
ments in changing TGF-1 protein expression. Fig 1
shows a reduction in the amount of TGF-1 expression
with Ad-AST and an increase in TGF-1 expression with
Ad-BAT. The overall expression of TGF-1s increased with
time.
Histologic changes with Ad-AST and Ad-BAT
treatments. Differences in morphology between the three
groups were most pronounced at the 12-week time point
(Fig 2). The original epigastric vein used for the vein graft
was a thin-walled vessel with only endothelial cells to the
inside of the internal elastic lamina. After 12 weeks, the
veins treated with Ad-CMVpLpA (control) showed a thick
neointimal layer consisting mostly of collagen to the inside
of the internal elastic lamina. The Ad-AST treatment
changed the morphometry of both the neointima and the
media/adventitia. In addition to being much thinner, the
neointima stained mostly for elastin and much less for
collagen. Themedia/adventitia layer contained areas of red
staining that were not seen in vein grafts from the Ad-
CMVpLpA or Ad-BAT groups. Under higher magnifica-
tion, these areas closely resemble the medial layer found in
artery. Individual cells that stain red were found even in the
regions of the media/adventitial layer that were mostly
collagen.
The Ad-BAT treatment resulted in vein grafts similar in
appearance to vein grafts from the Ad-CMVpLpA control
Table I. Vein graft collagen content (area in m2 stained
Treatment Time zero 1 wk
Neointimal
Control vein 594  19
Ad-AST 8,886  3,679
Ad-CMVpLpA 6,295  1,630
Ad-BAT 20,463  8,330
Medial/Adventitial
Control vein 64,430  10,653
Ad-AST 90,490  14,144
Ad-CMVpLpA 89,350  15,303
Ad-BAT# 166,216  27,949
‡P  .0001 vs Ad-CMVpLpA; §P  .0001 Ad-AST vs Ad-BAT; P  .00(a thick neointima and a thin acellular media/adventitia);however, the Ad-BAT neointima appeared to have more
nuclei than the Ad-CMVpLpA neointima.
To quantify the changes we observed in the morphom-
etry of the graft, we used image analysis of vein graft
sections harvested at 1, 2, 4, and 12weeks (n 5 vein grafts
for each treatment/time point). A threshold calibrated to
differentiate the green of our Gomori stain from all other
colors was used to measure the area of the cross section
occupied by collagen. Between 4 and 12 weeks, a large
increase was noted in the neointimal area of the cross
section occupied by collagen in control grafts. The Ad-AST
group had the lowest collagen content in the neointima at
2 and 4 weeks, but these differences were not statistically
significant. By 12 weeks, however, Ad-AST treatment had
significantly attenuated the increase in collagen in the neo-
intima (P  .0001 vs Ad-CMVpLpA and P  .0001 vs
Ad-BAT ) (Table I). Although Ad-AST lowered the colla-
gen content of the neointima of the vein grafts, Ad-BAT
raised the collagen content of the media/adventitia of the
vein grafts. For the Ad-BAT treatment, P  .0002 vs
Ad-CMVpLpA and P  .0001 vs Ad-AST for the increase
in collagen over time (Table I).
The open luminal area is known to depend not only on
the thickness of the neointima but also on expansive re-
modeling of the size of the vessel. Reanalyzing the data
using the perimeter of the internal elastic lamina as an
indication of the lumen size and subtracting the area of the
intimal hyperplasia gives an indication of the open lumen for
each treatment. Expansive remodeling did mitigate the effect
of the intimal hyperplasia found in the Ad-CMVpLpA and
Ad-BAT groups; however, the Ad-AST had the most open
luminal area at 4 and 12 weeks and reached statistical
significance at 12 weeks (P  .0004 Ad-AST vs Ad-
CMVpLpA and P .0004 Ad-AST vs. Ad-BAT; Ad-AST,
437,171  60,025 m2; Ad-CMVpLpA, 192,738 
25,008m2; Ad-BAT, 265,592 50,680m2) indicating
the prevention of collagen accumulation in the neointima
of the Ad-AST vein grafts allowed more open luminal area
to be retained in these vein grafts.
To further characterize the cell type (red histologic
staining) seen in Ad-AST grafts, we performed immuno-
histochemistry for smooth muscle actin (asm-1) and h-
n by Gomori stain)
2 wk 4 wk 12 wk
4,850  736 23,658  7,358 22,305  3,801‡§
7,173  1,885 33,366  15,838 362,017  63,239
1,160  5,796 30,421  6,395 443,111  120,340
2,610  28,809 92,623  18,169 172,115  63,680
6,649  21,946 123,414  29,150 245,926  81,675
0,888  60,826 381,632  45,506 374,302  59,143
d-MVpLpA; #P  .0001 Ad-AST vs Ad-BAT.gree
1
10
8
19caldesmon. Both smooth muscle cells and myofibroblasts
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caldesmon, whose expression is thought to be more
restricted to the nonsynthetic smooth muscle pheno-
type.14,15 At the 12-week time point, we found minimal
asm-1 staining (except for the staining of capillaries) in
the medial/adventitial layer of the Ad-CMVpLpA and
Ad-BAT groups. There were, however, large amounts of
diffuse neointimal asm-1 positive staining. In contrast,
grafts from the Ad-AST group showed medial asm-1 stain-
ing and neointimal asm-1 staining (Fig 3, left). The Ad-
AST group also showed much more h-caldesmon staining
than the Ad-CMVpLpA and Ad-BAT groups. For compar-
ison, h-caldesmon staining in unoperated vein and artery
controls is shown in Fig 3 (right).
Cross-sectional area staining for asm-1, h-caldesmon,
Fig 3. Immunohistochemistry for myofibroblasts and smooth
muscle cell markers. Left, Fitc-linked anti-asm1 (green). Right,
Anti-h-caldesmon primary antibody with Alexa-568 linked sec-
ondary antibody (red). The fluorescence picture layer (90%) is
overlaid on a bright field picture layer (10%) of the Sudan Black-
stained section for orientation of the fluorescent staining within
the section. Each treatment group shows asm-1–positive stain-
ing in the neointima. Ad-AST–treated grafts also show medial/
adventitial asm-1–positive staining and h-caldesmon–positive
cells. The two control tissues, epigastric vein and femoral artery,
also show asm-1 and h-caldesmon–positive staining (medial lay-
ers). Each photomicrograph was taken at original magnification
100.and CD68 over time and by treatments was measured bysetting the image analysis software to identify green fluo-
rescence or red fluorescence, as appropriate, for the
antibody-fluorochrome used on the section (Table II).
The Ad-CMVpLpA control showed a large stepwise in-
crease in asm-1–positive/h-caldesmon–negative cells in the
neointima between 2 and 4 weeks as the neointima devel-
oped. Because this increase was not linear in nature, t tests
on log-transformed data were used for neointimal asm-1
data instead of ANOVA. Ad-AST was effective (P  .01)
at reducing neointimal asm-1 at both 4 and 12 weeks
(Table II).
The Ad-CMVpLpA control also showed a large in-
crease in asm-1–positive/h-caldesmon–negative cells in the
media/adventitia out to 4 weeks, but medial/adventitial
staining for asm-1–positive/h-caldesmon–negative cells
decreased by 12 weeks. Both Ad-AST and Ad-BAT treat-
ments stimulated an early (at 1 week) increase in asm-1–
positive/h-caldesmon–negative cells in the in the media/
adventitia. At 12 weeks, Ad-AST had much more asm-1
staining in themedia/adventitia; however, this asm-1 stain-
ing corresponded with an increase in h-caldesmon staining,
indicating an increase in smooth muscle cells with Ad-AST
treatment. At 12 weeks, Ad-AST increased h-caldesmon
expression in the media adventitia (P  .0024 vs Ad-
CMVpLpA, P .04 vs Ad-BAT) and in the neointima (P
.0005 vs Ad-CMVpLpA, P  .005 vs Ad-BAT).
For all groups, CD68-positive cells were found through-
out the vein graft wall at 1, 2, and 4 weeks. At 12 weeks,
medial/adventitial macrophage numbers were greatly re-
duced from earlier time points, and most of the remaining
macrophages were found aligned along the lumen side of
the internal elastic lamina. Ad-AST resulted in reduced
CD68-positive cells (P  .005 vs Ad-CMVpLpA, P  .01
vs Ad-BAT) in the media/adventitia (Table II).
mRNA changes with Ad-AST and Ad-BAT treat-
ments. Wemeasured mRNA levels using qPCR specific to
collagen type 1 1 (Fig 4). Collagen mRNA is expected to
be highest at the early time points, as the vein remodels
itself to accommodate arterial pressures. By 12 weeks, most
remodeling of the vein wall has been completed and colla-
gen mRNA levels return to low levels. The results with
Ad-CMVpLpA reflect this progression, with a peak at 2
weeks and then decreasing collagen mRNA out to 12
weeks. At our earliest time point (1 week), the group that
received Ad-BAT, which causes an increase in TGF-1
expression, had 20 times more collagen mRNA than the
control group (Ad-CMVpLpA). Although the difference
between the Ad-BAT and control groups diminished at 2
weeks, at 4 weeks the Ad-BAT group again had very high
levels of collagen mRNA. The Ad-AST treatment resulted
in reduced levels of collagen mRNA. Although collagen
mRNA level was slightly elevated (but not statistically
significant vs Ad-CMVpLpA) at 1 week in the Ad-AST
group, at every time point after 1 week (2, 4, and 12
weeks), the Ad-AST treatment significantly reduced the
level of collagen mRNA in the vein graft (Fig 4).
Production of collagen is not the only factor influenc-
ing steady-state levels of collagen; the rate of breakdown of
vs Ad-
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Fig 4. Collagen messenger RNA (mRNA) level in vein grafts.
The grafts were harvested at the indicated time points, rinsed with
phosphate-buffered saline, homogenized, the mRNA extracted
and reverse transcribed, and measurements made by quantitative
polymerase chain reaction with normalization to mRNA levels of
hypoxanthine phosphoribosyltransferase (HPRT). Results from
ungrafted epigastric vein are given as time zero. Collagen mRNA
peaked at 2 weeks in the Ad-CMVpLpA group. Ad-AST signifi-
cantly reduced collagen mRNA at the latter time points; whereas,
Ad-BAT increased collagen mRNA. For each treatment/time
point (n 5 vein grafts). ‡P .01 vs Ad-CMVpLpA; *P .05 vs
Ad-CMVpLpA; §P .01 Ad-AST vs Ad-BAT; ¥P .05 Ad-AST vs
Ad-BAT. A significant time by-treatment effect was found, these
P values represent differences between treatment groups at each
time point. Error bars represent means  SEM.
Table II. Vein graft cross sectional area staining for asm-1
Treatment 1 wk
Neointimal
asm-1 Ad-AST 30  25
Ad-CMVpLpA 54  46
Ad-BAT 65  47
h-caldesmon Ad-AST 0  0
Ad-CMVpLpA 0  0
Ad-BAT 1  1
CD68 Ad-AST 114  78
Ad-CMVpLpA 31  22
Ad-BAT 307  197
Medial/Adventitial
asm-1 Ad-AST 1,884  531*
Ad-CMVpLpA 726  135
Ad-BAT 2,483  557‡
h-caldesmon Ad-AST 9  4
Ad-CMVpLpA 18  8
Ad-BAT 18  16
CD68 Ad-AST‘# 1,258  657
Ad-CMVpLpA 2,563  903
Ad-BAT 653  170
Epigastric vein stained 3,715  1,040 m2 for asm-1; 2,235  693 m2 f
Femoral artery stained 20,602  7,658 m2 for asm-1; 7,608  2,986 m
‡P  .01 vs Ad-CMVpLpA; *P  .05 vs Ad-CMVpLpA; §P  .01 Ad-AST
Ad-AST vs Ad-BAT.fibers. To this end, we measured the mRNA levels of matrixmetalloproteinases (MMP) 2 and 9. In the control group,
MMP-2 was highest at 2 and 4 weeks, with only a slight
elevation over the level seen in the unoperated epigastric
vein (both normalized to hprt) at 1 and 12 weeks. Com-
pared with Ad-CMVpLpA, the Ad-AST treatment did not
cause a significant change in MMP-2 mRNA; however, the
Ad-BAT treatment caused a significant (P  .0081 vs
Ad-CMVpLpA; P .0001 vs Ad-AST) increase in MMP-2
mRNA (Fig 5, top).
MMP-9 was increased many-fold in the control vein
graft (Ad-CMVpLpA) compared with unoperated vein
(75-fold at 1 and 2 weeks after surgery). The level then
decreased at the 4- and 12-week time points. Less MMP-9
(P .017) was seen with Ad-BAT treatment than was seen
in the Ad-CMVpLpA control, but the expression followed
the same pattern with time. Ad-AST caused a significant
drop in MMP-9 expression, P  .0001 vs Ad-CMVpLpA
and P  .033 vs Ad-BAT (Fig 5, bottom).
Fig 6 shows the levels of TIMP-1 with Ad-AST and
Ad-BAT treatments. Ad-AST clearly reduced the mRNA
for TIMP-1 (at one week, P  .0047 Ad-AST vs Ad-
CMVpLpA; P  .0001 Ad-AST vs Ad-BAT) and Ad-
BAT increased the mRNA for TIMP-1 (at one week, P
.048 Ad-BAT vs Ad-CMVpLpA). The reduction in
TIMP with Ad-AST treatment would allow more MMP
activity (decrease in collagen accumulation). The in-
crease in TIMP-1 with Ad-BAT treatment would prevent
MMP activity (increase in collagen accumulation).
Moreover, these changes were on the scale of hundreds
of mRNA per hprt mRNA whereas the changes shown in
Fig 5 (MMP-2 and MMP-9) were in the tens of copies
aldesmon, CD68 (area in m2)
2 wk 4 wk 12 wk
276  75 3,660  936‡§ 9,608  736‡§
196  89 15,993  3,773 22,795  2,048
647  264 27,235  8,004 30,465  4,588
0  0 28  12 1,419  126‡§
1  1 12  5 124  88
3  2 24  7 166  60
978  202 906  129 1,212  92
256  90 1,164  242 1,244  268
603  342 2,359  254 2,369  627
4,593  847 11,181  2,106 5,893  1,548‡§
5,592  650 8,614  1,699 932  246
7,673  1,417 21,111  6,347 1,984  814
2  1 365  71* 723  252‡¥
6  4 135  48 65  27
11  6 285  87 164  92
3,133  625 958  268 658  155
3,419  798 2,839  487 1,452  697
2,462  595 5,383  1,127 1,744  246
aldesmon; 6  5 for CD68.
h-caldesmon; 36  18 for CD68.
BAT; ¥P  .05 Ad-AST vs Ad-BAT; ‘P  .01 vs Ad-CMVpLpA; #P  .01, h-c
or h-c
2 forper HPRT mRNA.
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TGF-1 is a ubiquitous pleiotropic cytokine21 whose
effects vary with concentration,22,23 cell type,24,25 and the
effects of other signaling pathways.26,27 TGF-1 has long
been associated with increased production of the constitu-
ents of extracellular matrix.28 TGF-1 receptor phosphory-
lates Smad3, which translocates to the nucleus after associat-
ing with Smad4. The heteromeric complex then activates
target genes, including genes involved in extracellular ma-
trix synthesis. More recent techniques indicate that pro-
moters for the genes for the strands that make up collagen
I (col1a1 and col1a2) are targets for Smad3.29,30 In an
Fig 5. Levels of matrix metalloproteinase (MMP) messenger
RNAs (mRNAs) in vein grafts. Top, MMP-2 mRNA peaked at 2
weeks in the Ad-CMVpLpA group. Ad-AST did not significantly
change MMP-2 mRNA. Ad-BAT significantly increased MMP-2
mRNA. P  .01 vs Ad-CMVpLpA; #P  .01 vs Ad-AST.
Bottom, MMP-9 mRNA was highest at the early time points and
tapered off with time. Ad-AST significantly reduced the expression
of MMP-9 mRNA.‘P  .01 vs Ad-CMVpLpA; ●P  .05 vs
Ad-BAT. Ad-BAT also reduced the expression of MMP-9 mRNA
but this effect was weaker; ŒP  .05 vs Ad-CMVpLpA. These
P values represent differences between treatment groups across all
time points (there was not a significant time by treatment effect).
Results from ungrafted epigastric vein are given as time zero. For
each treatment/time point, n 5 vein grafts. Error bars represent
means  SEM.excellent example of coordinated control, timp1 is also aSmad3 target.30 TGF-1 can also stimulate collagen pro-
duction by a Smad-independent p38 mitogen-activated
protein kinase pathway.31
To interfere with TGF-1 gene expression and thus
study its effects during intimal hyperplasia development, we
transfected rat vein grafts ex vivo before implantation with
adenovirus that expressed mRNA antisense to TGF-1
(Ad-AST). This treatment resulted in decreased expression
of TGF-1 protein. The Ad-BAT treatment provided
mRNA for bioactive TGF-1 and increased the expression
of TGF-1 in the vein grafts. Ad-AST treatment resulted
in a dramatic diminution of collagen mRNA and the
amount of cross-sectional area staining positive for col-
lagen. This result is consistent with the results of Ryan et
al,32 who found that mRNA of fibrillar collagens and
adventitial collagen deposition was decreased without a
reduction in adventitial cell proliferation when they
blocked TGF-1 using soluble TGF-R:Fc via tail vein
injections.
In addition to removing a signal for production of
collagen, changing TGF-1 expression changes the cell
types that populate the vein graft. If the vein wall cells that
have responded to the treatments produce autocrine or
paracrine factors, effects would be seen beyond the dura-
tion of the original expression of the adenovirally delivered
mRNAs (approximately 2 weeks). TGF-1 is known to be
closely tied to the transition of fibroblasts to myofibro-
Fig 6. Tissue inhibitor of metalloproteinase 1 (TIMP-1)messen-
ger RNA (mRNA) level in vein grafts. Results from ungrafted
epigastric vein are given as time zero. In the Ad-CMVpLpA
control, TIMP-1 peaked at 4 weeks. In the Ad-BAT group,
TIMP-1 expression was significantly elevated by the treatment at 1
week. Both Ad-CMVpLpA and Ad-BAT showed reduced TIMP-1
expression with time. Ad-AST significantly reduced the expression
at of TIMP-1 (even to levels below that seen with the ungrafted
epigastric vein when both are normalized to hprt) at both early and
late time points. For each treatment/time point, n 5 vein grafts.
‡P .01 vs Ad-CMVpLpA; *P .05 vs Ad-CMVpLpA; §P .01
Ad-AST vs Ad-BAT. A significant time-by-treatment effect was
found. These P values represent differences between treatment
groups at each time point. Error bars represent means  SEM.
HPRT, hypoxanthine phosphoribosyltransferase.blasts.33,34 These myofibroblasts migrate from the adven-
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to have an antiapoptotic effect on myofibroblasts.36,37 The
peak in asm-1–positive/h-caldesmon–negative cells in the
Ad-BAT–treated group corresponds with a resurgence of
collagen mRNA in this group at 4 weeks. In addition, a
peak in CD68-positive cells (macrophage) is also seen at
this time point with Ad-BAT treatment; and macrophages
are known to stimulate the production of collagen by
myofibroblasts.
The Ad-AST treatment resulted in a prolonged dimi-
nution of TIMP-1 mRNA. The Ad-BAT treatment ele-
vated the TIMP-1 levels at the early time points. As a
compounding factor to slowing the breakdown of collagen,
TIMP-1 may also be involved in the fibroblast-to-myofi-
broblast transition.38 MMP-2 mRNA was elevated by the
Ad-BAT treatment but not reduced by the Ad-AST treat-
ment. Even though MMP-2 is involved in collagen break-
down, MMP-2 has been shown to be elevated by TGF-1
in cell culture.39 Also, MMP-2(–/–) mice have better allo-
graft survival times,40 so an increase in MMP-2 in the
treatment group (Ad-BAT) with the worst outcomes is not
completely unexpected. This effect may be because cells
sense their extracellular matrix environment,41 and
MMP-2 disruption of the extracellular matrix contributes
to the myofibroblast transition,42 MMP-2 contributes to
the ability of the cells to migrate to the neointima,11 or
because MMP-2 can cleave the TGF-1 latency associated
protein from TGF-1 stored in the extracellular matrix
(positive feedback loop). The increase in MMP-2 peaked a
little later than the increase in TIMP-1. Consequently, the
Ad-BAT group had high levels of MMP-2 but relatively
lower levels of TIMP-1 at 4 weeks. This may have contrib-
uted to less accumulation of collagen than would be pre-
dicted from the high collagen mRNA level seen at 4 weeks
in the Ad-BAT group.
MMP-9 andMMP-2 did not respond to the treatments
in the same way. Ad-AST reduced MMP-9 mRNA; how-
ever, a trend was also seen in the Ad-BAT group toward
reduced MMP-9 expression. A possible explanation might
be that Ad-AST is reducing the number of infiltrating cells
that can produce MMP-9, whereas Ad-BAT may be block-
ing MMP-9 production.43 The MMP-9 promoter contains
a nuclear factor-B binding site44 that the promoter for
MMP-2 does not have.45 This difference,46 or another
difference in the promoters, might be responsible for the
difference in response of the two genes to changes in
TGF-1 levels.
Although stenosis of the graft due to fibroproliferative
growth of the neointima is to be avoided, not all cell prolifer-
ation and remodeling of the vein wall is unhealthy.47 The rat
epigastric vein that was used in our vein graft model is a
relatively thin-walled vessel. In this respect, it is perhaps
analogous to the human cephalic vein, which has a thinner
medial layer than does the human saphenous vein. Patency
rates in human cephalic vein grafts are inferior to those of
saphenous vein grafts, with many graft failures resulting
from marked intimal hyperplasia. Ad-AST–treated vein
grafts had less intimal hyperplasia and more h-caldesmon–positive cells14-16 in the media/adventitia. These results
imply that the Ad-AST treatment prevented the transfor-
mation of smooth muscle cells into myofibroblasts, pro-
moted the proliferation of smooth muscle cells, or pro-
moted the migration of smooth muscle cells into the
remodeling vein graft.
CONCLUSION
With the Ad-AST and Ad-BAT treatments, we have
been able to tip the maturation of the vein graft toward
positive remodeling (artery like phenotype) or toward neg-
ative remodeling (fibroproliferation and stenosis), respec-
tively. These results emphasize the importance of TGF-1
as a gene therapy target to predispose the vein to respond
in a healthy way to being placed in the arterial environ-
ment.
Glen Leverson, PhD, of the Department of Surgery
Biostatistics Office assisted in the statistical analysis. Ad-
CMVpLpA(-) was provided by the University of Michigan
Medical Center Vector Core.
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